Cardiology Research and Practice Model∗ β1(CKD) β2(MetS) β3(CKD × MetS) Parameter CKD MetS CKD × MetS Estimated β 0.36 0.87 0.48 SE (β) 0.33 0.13 0.38 β1 (CKD) 0.1119220903 0.0087980044 −0.1097780898 Table 4: Output from proportional hazards models. ∗ Parameter estimates and test statistics for interaction between CKD (chronic kidney disease) and MetS (metabolic syndrome) adjusted for covariates. Table 5: Covariance matrix of the set of β coeﬃcients from the proportional hazards models. t-test 1.14 44.05 1.61 P value 0.29 0.0001 0.2 β2 (MetS) 0.0087980044 0.0173595635 −0.0170957203 HR 1.43 2.40 1.62 95% CI 0.74−2.75 1.85−3.10 0.77−3.44 7 β3 (CKD × MetS) −0.1097780898 −0.0170957203 0.1463599444 VAR(log S) = 0.125, SE(Log S) = 0.354. Hence, 95% conﬁ- dence interval estimate for SI, SI ± 1.96 × SE(SI) = (1.24 − 4.98). Acknowledgments Timothy M. Morgan Ph.D., Professor of Biostatistics, Public Health Division, at Wake Forest University provided input in statistics. This research was supported by NHLBI, NIH T32 training grant (2 T32 HL 076132-06 A1), and contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute. The authors thank the other investigators, the staﬀ, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org/. References [1] J. Coresh, D. Byrd-Holt, B. C. Astor et al., “Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 180–188, 2005. [2] J. Chen, P. Muntner, L. L. Hamm et al., “The metabolic syndrome and chronic kidney disease in U.S. adults,” Annals of Internal Medicine, vol. 140, no. 3, pp. 167–I39, 2004. [3] M. Kurella, J. C. Lo, and G. M. Chertow, “Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2134–2140, 2005. [4] M. P. Alexander, T. V. Patel, Y. M. K. Farag, A. Florez, H. G. Rennke, and A. K. Singh, “Kidney pathological changes in metabolic syndrome: a cross-sectional study,” American Journal of Kidney Diseases, vol. 53, no. 5, pp. 751–759, 2009. [5] J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. [6] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: ﬁndings from the Third National Health and Nutrition Examination Survey,” Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002. [7] J. H. Ix, M. G. Shlipak, G. M. Chertow, and M. A. Whooley, “Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coro- nary heart disease: data from the Heart and Soul Study,” Circulation, vol. 115, no. 2, pp. 173–179, 2007. [8] A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. [9] W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher, “Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular ﬁltration rate,” Clinical Chemistry, vol. 51, no. 2, pp. 321–327, 2005. [10] H. M. Lakka, D. E. Laaksonen, T. A. Lakka et al., “The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men,” Journal of the American Medical Association, vol. 288, no. 21, pp. 2709–2716, 2002. [11] A. S. Gami, B. J. Witt, D. E. Howard et al., “Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies,” Journal of the American College of Cardiology, vol. 49, no. 4, pp. 403–414, 2007. [12] M. G. Shlipak, L. F. Fried, M. Cushman et al., “Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors,” Journal of the American Medical Association, vol. 293, no. 14, pp. 1737–1745, 2005. [13] R. N. Foley, C. Wang, and A. J. Collins, “Cardiovascular risk factor proﬁles and kidney function stage in the US general population: the NHANES III study,” Mayo Clinic Proceedings, vol. 80, no. 10, pp. 1270–1277, 2005. [14] K. C. Chiu, A. Chu, V. L. W. Go, and M. F. Saad, “Hypovi- taminosis D is associated with insulin resistance and β cell dysfunction,” American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 820–825, 2004. [15] S. Williams, K. Malatesta, and K. Norris, “Vitamin D and chronic kidney disease,” Ethnicity & disease, vol. 19, no. 4, pp. S5–8, 2009. [16] P. S. Leung and M. C. Chappell, “A local pancreatic renin- angiotensin system: endocrine and exocrine roles,” Interna- tional Journal of Biochemistry and Cell Biology, vol. 35, no. 6, pp. 838–846, 2003. [17] T. Lau, P. O. Carlsson, and P. S. Leung, “Evidence for a local angiotensin-generating system and dose-dependent inhibition